State of the art biological therapies in pancreatic cancer.


Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a five-year survival rate of approximately 5%. Several target agents have been tested in PDAC, but almost all have failed to demonstrate efficacy in late phase clinical trials, despite the better understanding of PDAC molecular biology generated by large cancer sequencing… (More)
DOI: 10.4251/wjgo.v8.i1.55


Cite this paper

@article{Marco2016StateOT, title={State of the art biological therapies in pancreatic cancer.}, author={Mariacristina Di Marco and Elisa Grassi and Sandra Durante and Silvia Vecchiarelli and Andrea Palloni and Marina Macchini and Riccardo Casadei and Claudio Ricci and Riccardo Panzacchi and Donatella Santini and Guido Biasco}, journal={World journal of gastrointestinal oncology}, year={2016}, volume={8 1}, pages={55-66} }